Page 105 - Binder2

This isn’t a failure of the immune system.
It’s a failure of design.
A failure to work with the immune system’s architecture
instead of against it.
A failure to recognize that how a biologic is introduced is
just as important as what it’s made of.

If we want to prevent tolerization, we must stop designing
therapies that show up as threats.
We must stop relying on brute-force delivery and start
designing for biological familiarity.
We must stop treating the immune system like an obstacle
to outmaneuver and start treating it like a partner to
instruct.

Because in the end, immune tolerance isn’t about hiding.
It’s about earning acceptance.

And that starts with choosing delivery pathways, doses, and
formulations that speak the immune system’s language—
not shout over it.

And that means asking a very different set of questions
during the design of biologic therapies:

• How will this drug be introduced?
• What immune pathways will it engage?
• Will it be seen as familiar—or dangerous?

Because if we’re not designing for tolerance, we’re
designing for rejection.
And the immune system, as history has shown, will
eventually respond accordingly.

103